Durable Response to Chemoimmunotherapy of a Lung Adenocarcinoma Harboring a MET Exon 14 Skipping Mutation

por Nitta, Naohiro, Morimoto, Yoshie, Tani, Nozomi, Shimamoto, Takayuki
Publicado 2023

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)

por Yamada, Tadaaki, Uchino, Junji, Chihara, Yusuke, Shimamoto, Takayuki, Iwasaku, Masahiro, Tamiya, Nobuyo, Kaneko, Yoshiko, Kiyomi, Fumiaki, Takayama, Koichi
Publicado 2020

Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review

por Onoi, Keisuke, Chihara, Yusuke, Uchino, Junji, Shimamoto, Takayuki, Morimoto, Yoshie, Iwasaku, Masahiro, Kaneko, Yoshiko, Yamada, Tadaaki, Takayama, Koichi
Publicado 2020

Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer

por Katayama, Yuki, Shimamoto, Takayuki, Yamada, Tadaaki, Takeda, Takayuki, Yamada, Takahiro, Shiotsu, Shinsuke, Chihara, Yusuke, Hiranuma, Osamu, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Publicado 2019

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients

por Katayama, Yuki, Yamada, Tadaaki, Chihara, Yusuke, Tanaka, Satomi, Tanimura, Keiko, Okura, Naoko, Hirose, Kazuki, Uda, Sayaka, Shiotsu, Shinsuke, Hirai, Soichi, Hiranuma, Osamu, Harada, Taishi, Shimamoto, Takayuki, Iwasaku, Masahiro, Kaneko, Yoshiko, Uchino, Junji, Takeda, Takayuki, Takayama, Koichi
Publicado 2020